TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) versus placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC).